Behind the merger and relocation of GTx, the once-promising pillar of Memphis’ ‘biotech core’


“We had a commercial team, a marketing team, and the sales organization. … At the last minute, the FDA decided the data was not sufficient for approval.”

Previous Blue Cross CEO: Larger base of customers gives us more power for change
Next Activist investor looks to take over Scottsdale health care company board